1,669 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Graney & King LLC

Graney & King LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,669 shares of the company’s stock, valued at approximately $241,000.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Borer Denton & Associates Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Borer Denton & Associates Inc. now owns 64,035 shares of the company’s stock valued at $9,261,000 after acquiring an additional 355 shares during the period. Core Wealth Partners LLC raised its position in Johnson & Johnson by 4.6% during the 4th quarter. Core Wealth Partners LLC now owns 14,474 shares of the company’s stock worth $2,093,000 after purchasing an additional 635 shares during the last quarter. America First Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 1.1% in the fourth quarter. America First Investment Advisors LLC now owns 127,814 shares of the company’s stock valued at $18,484,000 after buying an additional 1,377 shares during the period. Ausdal Financial Partners Inc. raised its position in shares of Johnson & Johnson by 5.7% during the fourth quarter. Ausdal Financial Partners Inc. now owns 9,828 shares of the company’s stock worth $1,421,000 after acquiring an additional 527 shares during the last quarter. Finally, TrueMark Investments LLC boosted its holdings in Johnson & Johnson by 48.7% in the fourth quarter. TrueMark Investments LLC now owns 34,807 shares of the company’s stock valued at $5,034,000 after acquiring an additional 11,399 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Barclays lifted their target price on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Bank of America increased their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 5th. Raymond James cut their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Leerink Partners decreased their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $161.14 on Wednesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a 50 day simple moving average of $157.70 and a two-hundred day simple moving average of $156.14. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a market capitalization of $388.32 billion, a price-to-earnings ratio of 24.23, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business earned $2.29 EPS. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.